Wall Street

Amgen’s Lumakras combination data held for August lung cancer meeting

Published by

By Deena Beasley (Reuters) – Trial data on Amgen Inc’s Lumakras will be released later on Tuesday by the World Conference on Lung Cancer (WCLC), but meeting organizers decided to hold until Aug. 7 results from a study in combination with drugs that help the immune system attack cancer. The study, which will be the first report of how well Lumakras works in combination with immunotherapies – Merck & Co’s Keytruda and Roche Holding AG’s Tecentriq – was selected to be part of the press program at the organization’s Vienna meeting, WCLC spokesman Chris Martin said on Tuesday. Lumakras is an oral d…

Read More

Share this Story
Load More Related Articles
Load More In Wall Street